|
Oncology Competitive Intelligence Leaders
Potential game changers: Late-stage readouts at ASCO/EHA: Selinexor: The last of the wave of novel MOA + ruxolitinib pivotal trials in frontline myelofibrosis (MF). All in this wave have faced struggles, selinexor included, with a missed symptom endpoint in Phase III SENTRY. Detailed outcomes reported at ASCO will inform not only the next steps for selinexor, but future development in the field of first-line MF as a whole.
Executive Summary: ONCrg’s PhD analysts review the most significant early-stage oncology developments from AACR 2026 and preview key data expected at ASCO, covering cell therapies, antibody-drug conjugates (ADCs), immuno-oncology, and the DNA damage response (DDR) space.
Oncology Resource Group goes beyond the abstracts to discuss what really happened at AACR 2026.
Excerpt from Custom Post Type Indication: ECS
Executive Summary: ONCrg analyst Sarah Lockheed previews four late-breaking phase 3 readouts at ASCO GU 2026 covering the post-CPI RCC setting, adjuvant RCC, and perioperative and advanced bladder cancer — all centered on belzutifan combinations and the continued expansion of the enfortumab vedotin plus pembrolizumab franchise.
Executive Summary: ONCrg analyst Patrick Nygren previews the highest-impact clinical presentations across hematologic malignancies at ASH 2025, covering CLL, multiple myeloma, NHL, and AML, with a focus on practice-changing phase 3 readouts and early-stage combination signals.